Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

Yi Wen Wang, Wei Ming Li, Wen Jeng Wu, Chee Yin Chai, Tsuey Yu Chang, Yin Sun, Chih Jen Cheng, Yow Ling Shiue, Shu Jem Su, Hong Lin Cheng, Hsiao Sheng Liu, Nan Haw Chow

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

Original languageEnglish
Pages (from-to)709-719
Number of pages11
JournalAmerican Journal of Pathology
Volume183
Issue number3
DOIs
Publication statusPublished - 2013 Sep

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract'. Together they form a unique fingerprint.

Cite this